CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $520K rose 23.5% year over year, ahead of the +3.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 39.8% from the prior quarter.

Context

  • Depreciation & amortization amounted to 46.9% of revenue in FY2025, down 213.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +23.5% holds above the trailing-twelve-month pace of +3.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$520K+39.8% QoQ
Last fiscal yearDec 2025
$1.64M-3.4% YoY
LTMMar 2026
$1.74M+3.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.5%——
1 year-3.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.64M USD
Year-over-year change
-3.4%
4-year CAGR
-48.2%

Depreciation & Amortization vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.4% is the 4th highest of 9, against a peer median of -19.5%.
  • Depreciation & amortization amounts to 44.2% of revenue for CAMP, versus a peer median of 12.4%.
CAMP Competitors
Depreciation & Amortization for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$7.74M USD-13.3%+13.9%3.0%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$2.28M CAD-57.9%+10.7%12.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$1.74M USD+3.4%—44.2%
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.56M USD+35.6%-2.9%823.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.21M USD+8.3%+36.2%—
BMEABiomea Fusion, Inc.LTM Mar 2026$960K USD-46.5%+26.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K USD+132.3%+52.6%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K USD-25.8%+27.3%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$131K USD-84.0%-41.1%—
Peer median (excluding CAMP) —-19.5%+20.4%12.4%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(27.99M)(44.19M)(49.29M)(51.79M)(80.4M)
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
Deferred Income Tax00000
Stock-Based Compensation11.32M1.38M2.91M4.03M4M
Change in Working Capital1.59M373K(154K)(1.88M)13.01M
Accounts Receivables1.44M0000
Inventory5.16M0000
Accounts Payables0000(1.03M)
Other Working Capital(5.01M)373K(154K)(1.88M)14.04M
Other Non-Cash Items(11.94M)3.02M705K2.39M32.21M
Operating Cash Flow(4.22M)(38.54M)(44.16M)(45.56M)(29.55M)
Capital Expenditures(13.3M)(4.03M)(678K)(441K)(279K)
Acquisitions (Net)000036K
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities5.72M0000
Investing Cash Flow(7.58M)(4.03M)(678K)(441K)(243K)
Debt Repayment—(93K)116K(824K)(208K)
Common Stock Issued000061.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(2.64M)100.25M185K72.49M14.93M
Financing Cash Flow(2.64M)100.16M301K71.66M75.89M
Effect of Forex Changes(965K)25.6M000
Net Change in Cash(15.4M)83.19M(44.53M)25.66M46.09M
Free Cash Flow(17.52M)(42.57M)(44.83M)(46M)(29.83M)

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.